DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases

(2020) Juan A. Molina-Guarneros et al.   International Journal of Clinical Pharmacy

Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population‐based cohort study

(2020) M.S.M. Persson et al.   BRITISH JOURNAL OF DERMATOLOGY

Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey

(2020) Phuc Le et al.   DIABETES CARE

Association Between Medication Use and Bullous Pemphigoid

(2020) Sian-De Liu et al.   JAMA Dermatology

Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes

(2019) Seon Gu Lee et al.   JAMA Dermatology

Case–non-case studies: Principle, methods, bias and interpretation

(2019) Jean-Luc Faillie   THERAPIE

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes

(2019) Antonios Douros et al.   DIABETES CARE

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

(2019) Kaisa Tasanen et al.   Frontiers in Immunology

Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®

(2019) Carla Carnovale et al.   Expert Opinion On Drug Safety

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database

(2019) Alejandra Reolid et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database

(2018) Masanori Arai et al.   DIABETES CARE

Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case control study

(2018) O. Varpuluoma et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

(2018) Michael Benzaquen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes

(2018) Khalaf Kridin et al.   JAMA Dermatology

Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review

(2018) Patrick M. Jedlowski et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls

(2017) B. Sim et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade

(2017) L. Fania et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database

(2016) J. Béné et al.   BRITISH JOURNAL OF DERMATOLOGY

Update on the pathogenesis of bullous pemphigoid: An autoantibody-mediated blistering disease targeting collagen XVII

(2014) Wataru Nishie   JOURNAL OF DERMATOLOGICAL SCIENCE

Pemphigoid diseases

(2012) Enno Schmidt et al.   LANCET